Advertisement
Advertisement
U.S. markets close in 14 minutes
Advertisement
Advertisement
Advertisement
Advertisement

Hillstream BioPharma, Inc. (HILS)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
0.8299+0.0259 (+3.22%)
As of 03:36PM EDT. Market open.
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Momentum

Momentum

Previous Close0.8040
Open0.7980
Bid0.8000 x 1100
Ask0.8300 x 1100
Day's Range0.7901 - 0.8391
52 Week Range0.6500 - 4.2400
Volume18,694
Avg. Volume225,553
Market Cap9.569M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for HILS

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Hillstream BioPharma, Inc.
    Daily Spotlight: VIX Back to 30Fear has returned to the equity market, as inflation readings have failed to cool dramatically, the Federal Reserve remains on a long-term course toward higher rates, U.S. mid-term elections approach, Vladimir Putin threatens the use of nuclear weapons in Eastern Europe, and the global economy reels toward recession. The VIX Volatility Index is a key gauge of investor sentiment and has been elevated above 20 for most of the past two years. Last Friday, after a 486-point drop in the Dow Jones Industrial Average, the VIX closed at 29.92 after touching 32 earlier in the day. A little more than a month ago, the VIX was below 20, and seemingly headed lower as the U.S. consumer economy appeared to be in good shape. How can the market turn so quickly? Investors are always looking ahead, and the latest data (the CPI two weeks ago, the Fed's 75-basis-point hike last week) point toward near-term challenges for the economy, companies, and corporate earnings. New data will be out this week (the Fed's favorite inflation gauge, the PCE indices) and corporate earnings reports will start to flow in mid-October. We expect volatility to remain high, yet the pullback in stock prices unearths some attractive valuations. Buy low and sell high. We think investors should continue to focus on well-managed companies with clear growth objectives and clean balance sheets.
    Rating
    Fair Value
    Economic Moat
    2 days agoArgus Research
View more
  • GlobeNewswire

    Hillstream BioPharma to Participate in the Fierce Biotech Summit on September 19-20

    BRIDGEWATER, N.J., Sept. 14, 2022 (GLOBE NEWSWIRE) -- Hillstream BioPharma, Inc. (Nasdaq: HILS) (“Hillstream” or the “Company”), a biotechnology company developing novel therapeutic candidates targeting ferroptosis, an emerging new anti-cancer mechanism resulting in iron-mediated cell death for drug resistant and devastating cancers, will participate in the Fierce Biotech Summit, being held at The Westin Copley Place in Boston, on September 19-20, 2022. Mr. Randy Milby, Founder and Chief Executi

  • GlobeNewswire

    Hillstream BioPharma to Attend the 12th Annual World Orphan Drug Congress USA on July 11-13

    BRIDGEWATER, N.J., July 08, 2022 (GLOBE NEWSWIRE) -- Hillstream BioPharma, Inc. (Nasdaq: HILS) (“Hillstream” or the “Company”), a biotechnology company developing novel therapeutic candidates targeting ferroptosis, an emerging new anti-cancer mechanism resulting in iron mediated cell death for drug resistant and devastating cancers, will attend the 12th Annual World Orphan Drug Congress USA 2022, being held at the Hynes Convention Center in Boston, on July 11-13, 2022. Mr. Randy Milby, Founder a

  • GlobeNewswire

    Hillstream BioPharma Announces Collaboration with Sapien Biosciences in Cancer Treatments

    Investigating the synergy between HSB-1216, a Ferroptosis inducer, and Immune Checkpoint InhibitorsBRIDGEWATER, N.J., June 27, 2022 (GLOBE NEWSWIRE) -- Hillstream BioPharma, Inc. (Nasdaq: HILS) (“Hillstream” or the “Company”), a biotechnology company developing novel therapeutic candidates targeting ferroptosis, an emerging new anti-cancer mechanism resulting in iron mediated cell death for drug resistant and devastating cancers, today announced a collaboration with Sapien Biosciences to evaluat

Advertisement
Advertisement